AETHLON MEDICAL (AEMD) Company Report

Aethlon Medical, Inc. announced a private placement and warrant inducement expected to generate approximately $3.3 million in gross proceeds.
The private placement involves the purchase of 595,897 shares of common stock (or pre-funded warrants) and warrants to purchase up to an aggregate 1,042,820 shares of common stock, with a combined effective offering price of $4.03 per share.
The company also entered into a warrant inducement agreement, reducing the exercise price of outstanding March 2025 and September 2025 warrants to $4.03, leading to the exercise of 155,000 shares and 55,555 shares, respectively.
In consideration for the immediate exercise of these warrants, Aethlon Medical agreed to issue new unregistered warrants to purchase an aggregate of 368,471 shares.
The offering is expected to close on or about December 8, 2025.

Dec 5, 2025, 2:15 PM

Aethlon Medical Reports Q2 2026 Financials and Advances Oncology Trial

AEMD

Earnings

New Projects/Investments

Aethlon Medical reported a cash balance of approximately $5.8 million as of September 30, 2025.
For the fiscal second quarter ended September 30, 2025, consolidated operating expenses decreased by $1.4 million, or 48%, to $1.5 million, resulting in an operating loss of $1.5 million.
The company successfully completed chemopurifier treatments for three participants in cohort one of its Australian oncology trial without device deficiencies or serious adverse events, leading to the recommendation to advance to cohort two on July 11, 2025.
Initial data from cohort one showed decreases in large extracellular vesicles (EVs), including those with PD-L1, and improvements in laboratory ratios associated with immunotherapy responses in some participants.
Aethlon is also advancing preclinical R&D, including presenting data on the chemopurifier's binding to Long COVID-related extracellular vesicles and signing a Material Transfer Agreement (MTA) to develop a simplified chemopurifier system.

Nov 12, 2025, 9:30 PM

Aethlon Medical Reports Fiscal Q2 2025 Financial Results and Corporate Update

AEMD

Earnings

New Projects/Investments

Delisting/Listing Issues

Aethlon Medical reported a cash balance of approximately $5.8 million as of September 30, 2025.
The company achieved a 48% reduction in operating expenses, which totaled $1.5 million for the fiscal second quarter ended September 30, 2025, compared to the prior year.
Recruitment is underway for Cohort 2 of the Australian oncology trial for the Hemopurifier under an amended protocol.
Aethlon Medical maintained its Nasdaq listing after resolving compliance matters.